Floatz logo

Sargramostim

Stage III Pancreatic Cancer

Barbara Ann Karmanos Cancer Instituteprotein_peptidePhase 1/2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Stage III Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Dai, Guanghai
Phase 3BBB
Irinotecan
NRG Oncology
Phase 3BB
FLUTICASONE
Barbara Ann Karmanos Cancer Institute
Phase 1/2B
Cediranib
National Cancer Institute (NCI)
Phase 2B
Nelfinavir
University of Nebraska
Phase 2B

View all 21 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →